LE WE PMID CA
Sorafenib4351Sorafenib

ABT737

Amonafide AS1413 ttIntercalator

ARRY520 ttKSP

Axitinib

Azacitidine

AZD1152 ttAuroraB

AZD6244 ttMEK

BCL2

BehenoylaraC ttProdrugAraC

Bevacizumab ttVEGF

CAR coxsackie and adenovirus receptor

CD95 FAS Apo1

Clofarabine

Decitabine

Elacytarabine

Everolimus

Fbw7 Sel10 hCdc4 Ago

Interleukin24 MDA7

Kidney (Neoplasia RCC)

Kidney (Neoplasm)

KSP Kinesin spindle protein

Leukemia (acute myeloic)

Leukemia (T cell)

Liver (Neoplasia HCC)

MCL1

Motesanib

Neoplasia (Oncolytic virus)

Pazopanib

Pegaptanib

Ranibizumab ttVEGF

Ribavirin

Sapacitabine

Sorafenib

Sunitinib

Temsirolimus

Terameprocol ttSurvivin ttCDK1

Thyroid (Neoplasia)

Tipifarnib

Vadetanib

Voreloxin ttIntercalator

Vorinostat ttHDAC

XL184

2010  
1
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
[20028613] Health Technol Assess 14(2): 1-184, iii-iv (2010)
2008  
2
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.
[18852116] Mol Cancer Ther 7(10): 3129-40 (2008)
2007  
3
Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib.
[17591826] Ann Oncol 18 Suppl 6(-): vi22-5 (2007)
2007  
4
CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
[17606705] Clin Cancer Res 13(13): 3765-70 (2007)
2006  
5
Sorafenib for the treatment of advanced renal cell carcinoma.
[17189398] Clin Cancer Res 12(24): 7271-8 (2006)
2011  
6
Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.
[21383525] Endocr J 58(3): 151-3 (2011)
2010  
7
Targeted therapy for renal cell cancer: current perspectives.
[21122471] Discov Med 10(54): 394-405 (2010)
2007  
8
Vascular endothelial growth factor: biology and therapeutic applications.
[17537667] Int J Biochem Cell Biol 39(7-8): 1349-57 (2007)
2008  
9
Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.
[18695262] Oncologist 13(8): 845-58 (2008)
2009  
10
2010  
11
Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.
[21090521] Isr Med Assoc J 12(10): 628-32 (2010)
2011  
12
Mcl-1 ubiquitination and destruction.
[21608150] Oncotarget 2(3): 239-44 (2011)
2011  
13
Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery.
[20948318] Cancer Biol Ther 10(12): 1290-305 (2011)
2010  
14
Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights.
[20416083] J Hematol Oncol 3(-): 17 (2010)
2011  
15
Sorafenib for advanced hepatocellular carcinoma: a systematic review.
[21375938] Zhongguo Yi Xue Ke Xue Yuan Xue Bao 33(1): 51-7 (2011)
PMC   
16
The role of sorafenib in downsizing hepatocellular carcinoma prior to liver transplantation and in treating tumor recurrence.
[24713719] Ann Gastroenterol 24(3):228-230 (2011)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.



  • Sorafenib

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia